The SURPASS trials demonstrated the efficacy and safety of tirzepatide for type 2 diabetes. Dr Carol Wysham (MultiCare Rockwood Clinic, Spokane, WA, USA) discusses the outcomes of a post-hoc analysis of the SURPASS programme and the impact of tirzepatide on clinical practice following its recent FDA approval.
The abstract entitled ‘Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- What has the SURPASS clinical trial programme taught us about the efficacy and safety of tirzepatide in the treatment of patients with type 2 diabetes? (0:25)
- Which subpopulations were evaluated in the post-hoc analysis you are presenting? (1:25)
- What were the findings of these analyses? (1:56)
- What is the safety profile of tirzepatide? (2:46)
- Following the recent FDA approval of tirzepatide, what do you expect to be its impact on clinical practice? (3:40)
Disclosures: Carol Wysham has received grant/research support from Abbott, Corcept, Eli Lilly, Novo Nordisk, Regeneron and Vanda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
